EARLY CONFIRMED SPEAKERS

 

We are working hard to create the best agenda yet, and to make sure we invite the most excellent speakers to speak at the congress in 2020.

We have already confirmed over 130 out of 350+ speakers, and the list is ever growing.

 

  • Dr Ofer Levy, Professor of Pediatrics, Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School

  • Dr Derek O'Hagan Senior Advisor in R&D, GSK Vaccines 

  • Dr Wolfgang Leitner, Chief, Innate Immunity Section, Basic Immunology Branch, NIH

  • Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, & Government Affairs, Merck

  • Dr Leonard Friedland, VP, Scientific Affairs and Public Health, GSK

  • Dr Matt Hepburn, Former  Program Manager, DARPA

  • Larry Wolfraim, Program Officer Biodefense Vaccines and other Biological Products Development Section Office of Biodefense, Research Resources, and Translational Research 

  • Dr Graham Taylor, Senior Lecturer in Tumour Immunology, Institute of Immunology and Immunotherapy, University of Birmingha

  • Dr Olivera Finn, Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine

  • Dr Fred Ramsdell, CSO, Parker Institute for Cancer Immunotherapy 

  • Dr Karolina Palucka, Professor, Principal Investigator, Distinguished Professor, Department of Immunology, The Jackson Laboratory

  • Dr Elizabeth Mittendorf, Associate Professor for Department of Surgical Oncology, Dana-Farber / Brigham and Women's Cancer Center

  • Dr Emmett Schmidt, Associate Vice President, Merck

  • Dr Benjamin Vincent, Assistant Professor, Division of Hematology/ Oncology, UNC Lineberger Comprehensive Cancer Center

  • Dr Adrian Wildfire, Scientific Director - Infectious Diseases & Human Challenge Unit, SGS

  • Dr Cynthia Dukes, VP, Scientific and Clinical Services and Head of Vaccine Center of Excellence, ICON

  • Dr Darin Seehafer, Sr. Clinical Scientist, PRA

  • Dr Mark Alderson, Director - Pneumococcal Vaccine Project Vaccine Development Global Program, Path

  • Dr Mary Marovich, Director of Vaccine Research Program, NIH

  • Dr Louis Picker, Managing Director, Oregon Health & Science University

  • Dr Daria Hazuda, CSO & Vice President of Infectious Diseases Discovery, Merck

  • Dr Philip Krause, Deputy directoer, CBER, FDA

  • Dr Patrick Emmet Duffy, Chief, Laboratory of Malaria Immunology and Vaccinology, NIH

  • Dr Will Singleterry, Director, Scientific Collaborations, IsoPlexis 

  • Dr Bibhash Mukhopadhyay, Principal, New Enterprise Associates

  • Dr Tim Cooke, Senior Vice President, Commercial Business, Ology Bioservices & NVPO

  • Dr Stephen Hoffman, CEO, Sanaria

  • Dr Malte Meppens, Head of Drug Product Development, GSK

  • Senior Representative, Sartorius Stedim Biotech 

  • Senior Representative, Ology Bioservices

  • Senior Representative, Paragon (Catalent)

  • Senior Representative, Batavia Bio

  • Senior Representative, Institute for Translational Vaccinology

  • Senior Representative, ExpreS2ion Biotechnologies

  • Dr Jim Wassil, Vice President and GH&V BU Head, Vaccines, Pfizer

  • Dr Richard Hughes, Principal, Avalere Health

  • Dr Saad Omer, Director, Yale Institute for Global Health; Associate Dean (Global Health Research) & Professor of Medicine, Yale School of Medicine

  •  Dr Inci Yildirim Associate Professor, Emory University 

  • Dr Mario Roederer, Chief Of Immuno-Technology, NIH

  • Nikolai Petrovsky, Chairman, Flinders University

  • Roman Chicz, Associate Vice President and Global Head, External Research and Development, Sanofi 

  •   Dr Michael Salgaller, Supervisor, Invention Development and Marketing Unit (IDMU)   Technology Transfer Center, NCI

  • Dr Barry Datlof, Chief, Business Development And Commercialization, U.S. Army Medical Research and Materiel Command

  •   Dr Michael Mowatt, Director, Technology Transfer And Intellectual Property Office, National Institute of Allergy and Infectious Diseases

  •   Dr Gary Nabel, CSO, Sanofi

  •   Dr Richard Hatchett, CEO, CEPI

  •   Dr Greg   Poland,   Director, Mayo

  • Dr Paul  Offit, Chief Division of Infectious Diseases & Director of the Vaccine Education Center, Children’s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania

  • Dr Roy Baynes, Senior Vice President and Head Global Clinical Development, Chief Medical Officer,  Merck Research Laboratories

  •   Dr, Anthony Fauci, NIAID Director, NIH

  •   Dr Rino Rappuoli, Chief Scientist, GSK

  • Dr Kate O'Brien, Director, Department of Immunization, Vaccines and Biologicals, WHO

  •   Dr Jean-Jacques Muyembe-Tamfum, Director-General, National Institute for Biomedical Research, Democratic Republic of the Congo (DRC) & Professor of Microbiology, Kinshasa University Medical School

  •   Dr John Markels, President, Merck

  • Dr Peter Hotez Dean, Professor, Co-Head of Pediatric Tropical Medicine,  Baylor College of Medicine & Co-Director, Texas Children’s Hospital Center for Vaccine Development

  • Dr Ann  Ginberg, Senior Technical Advisor, IAVI

  • Dr Peter Palese, Horace W. Goldsmith Professor and Chair, Department of Microbiology, Professor, Department of Medicine, Icahn School of Medicine at Mount Sinai

  • Dr Kathryn Edwards, Professor of Pediatrics, Vanderbilt 

  • Dr Ilse Dieussaert, Director and Head of Maternal Immunization Vaccine Development, GSK

  • Senior Representative,  Neomed Labs 

  • Senior Representative, hVIVO

  • Senior Representative, Medicago

  • Senior Representative, Viroclinics

  • Dr Barney Graham, Deputy Director, VRC, NIAID NIH

  • Brian Abramson, Attorney and Treatise Author

  • Bruno Speder, Head Clinical Regulatory Affairs, Consultancy, SGS

  • Lynlee Burton Senior Director, Therapeutic Expertise – Vaccine PRA

  • Senior Representative, rho

  • Senior Representative, Lumacyte

  • Senior Representative, Celerion

  • Dr James Cummings, President, ICON Government and Public Health Solutions, ICON Clinical Research

  • Dr Cynthia Derdeyn, Professor, Emory Vaccine Center

  • Dr Walter Straus, Associate Vice President, Therapeutic Area Head, Clinical Safety And Risk Management Merck Research Laboratories

  • Dr Scott Halstead, Adjunct Professor, Department Of Preventive Medicine And Biometrics, Uniformed Services University of Health Services

  • Dr Daniel Salmon, Director, Institute for Vaccine Safety Johns Hopkins Bloomberg School of Public Health 

  • Dr Raina MacIntyre, Principal Research Fellow and Professor of Global Biosecurity, University of New South Wales 

  • Dr Yenlik Zheteyeva, Director, Clinical Safety and Risk Management, Merck Research Laboratories 

  • Dr Angus Thomson, Head, Vaccine Confidence and Coverage, Global Public Affairs, Sanofi Pasteur

  •  Dr Bob Chen, Scientific Director, Brighton Collaboration

  • Dr Anna Durbin Professor, International Health, Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health

  •  Professor Holly Seale, Senior Lecturer, School of Public Health and Community Medicine, University of New South Wales

  • Mr William McGillian, Associate Director Supply Chain Management, Product Handling and Technology, Merck

  • Senior Representative, Marken 

  • Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen

  • Senior Representative, PPD

  • Senior Representative, 360 Biolabs

  • Senior Representative, CanSino Biologics 

  • Dr Jon Henrich, Associate Vice President and Segment Head,
    Sanofi

  • Dr John Mascola, Director of the Dale and Betty Bumpers Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), NIH

  • Dr Maura Kibbey, Senior Scientific Fellow, Education & Training, Global Biologics, USP

  •  Ashley Kalinauskas, Founder & CEO, Torigen Pharmaceuticals

  •  Dr Patricia Lawman, CEO, Morphogenesis

  • Dr GS Reddy, SVP, Brilliant Bio Pharma Private Limited, Hyderabad, India

  • Dr Cyril Gay, Senior National Program Leader, Office of National Programs USDA

  • Dr Douglas Thamm, Professor of Oncology, Director of Clinical Research Colorado State University

  • Dr Stephen Johnston, Director, Biodesign Institute, Arizona State University

  • Dr Philip Buck, Head, US Health Outcomes, Vaccines, GSK

  • Dr M. Suresh Marulasiddappa, John E. Butler Professor of Comparative and Mucosal Immunology, Director, Comparative Biomedical Sciences Graduate Program, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison

  • Dr Mahesh Kumar, SVP, Zoetis 

  • Dr Lisa Conti, Director of Strategic Initiatives and Chief Science Officer, Florida Department of Agriculture and Consumer Services

  • Dr Ken Stuart, Founder and Professor, Center for Infectious Disease Research

  • Dr Andrew Hillier, Associate Director, Zoetis

  • Dr Flor Munoz Rivas, Associate Professor, Baylor College of Medicine

  • Dr Octavio Ramilo, Physician - Infectious Disease, Nationwide Children's Hospital

  • Dr Lakshmi Sukumaran, Medical Officer, Centers for Disease Control and Prevention

  • Dr Javad Aman, President and CSO, Integrated Biotherapeutics

  • Dr Nadia Cohen, Alliance Manager, Carb-x

  • Dr Gwo-Yu, Co-Head and Staff Scientist, NIH

  • Dr Nadine Rouphael, Emory

  • Vanitha Sekar, Executive Director, Merck

  • Dr Jay Evans, Director, Center for Translational Medicine, University of Montana

  • Dr Stanley Plotkin, Vaxconsult

  • Dr Mark Esser, VP, Microbial Sciences AstraZeneca

  • Dr Tonya Villafana, AstraZeneca

  • Senior Representative, Essential Medicines Group, PATH

  • Dr Laurent Humeau, CSO, Inovio

  • Dr Lauren Wood, CMO, PDS Biotech

  • Dr Cristiana Campa, Head QbD Integration, GSK Vaccines

  • Dr Elke Bergmann-Leitner, Chief, Immunology Core, Malaria Biologics Branch, Walter Reed Army Institute of Research 

  • Dr Rama Amara, Professor, Emory

  • Charles Gleason, CEO/ CFO, Liberty Ventures 

  • Daniel Wolf, BARDA

  • Andreas Kuhn Senior Vice President RNA Biochemistry & Manufacturing, BioNtech

  • Dr Angela Shen, Professor & Public Health Consultant, Drexel Dornsife School of Public Health, CAPT (ret) US Public Health Service

  • Dr Ruslan Novosiadly, Oncology Translational Medicine Team Lead, BMS